Literature DB >> 24234325

Lupus nephritis: review of the literature.

Adeel Zubair, Marianne Frieri.   

Abstract

Physicians in practice should be knowledgeable regarding several aspects of autoimmune disorders, especially systemic lupus erythematosus (SLE) and lupus nephritis. These disorders can present to the clinician's clinic and private office regardless of their specialty. This review will discuss various aspects of SLE, its mechanisms of disease, role of accelerated atherosclerosis, proinflammatory cytokines, and therapeutic approaches. The role of vascular endothelial growth factor in which and plasma levels have been associated with disease activity, classification of severity, and diagnosis of lupus nephritis is addressed. Current treatment options, prognosis, and future therapeutic approaches and common side effects are also discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24234325     DOI: 10.1007/s11882-013-0394-4

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  67 in total

1.  Sequential therapies for proliferative lupus nephritis.

Authors:  Chee-Seng Yee; Caroline Gordon
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

Review 2.  Treatment of lupus nephritis.

Authors:  Sebastian Dolff; Jo Hm Berden; Marc Bijl
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

3.  Clinical characteristics of concurrent and sequentially presented lupus-related protein-losing enteropathy: what are their differences?

Authors:  Siu-Tong Law; Kwok Man Ma; Kin Kong Li
Journal:  Rheumatol Int       Date:  2012-01-05       Impact factor: 2.631

Review 4.  A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis.

Authors:  Andrew Smyth; Guilherme H M Oliveira; Brian D Lahr; Kent R Bailey; Suzanne M Norby; Vesna D Garovic
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 8.237

5.  From the Large Scale Expression Analysis of Lupus Nephritis to Targeted Molecular Medicine.

Authors:  Celine C Berthier; Matthias Kretzler; Anne Davidson
Journal:  J Data Mining Genomics Proteomics       Date:  2012-03-27

6.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

Review 7.  Lupus nephritis: where are we now?

Authors:  Liz Lightstone
Journal:  Curr Opin Rheumatol       Date:  2010-05       Impact factor: 5.006

8.  Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice.

Authors:  H Ogawa; H Kameda; K Amano; T Takeuchi
Journal:  Lupus       Date:  2009-12-01       Impact factor: 2.911

9.  European consensus statement on the terminology used in the management of lupus glomerulonephritis.

Authors:  C Gordon; D Jayne; C Pusey; D Adu; Z Amoura; M Aringer; J Ballerin; R Cervera; J Calvo-Alén; C Chizzolini; Jm Dayer; A Doria; F Ferrario; J Floege; L Guillevin; M Haubitz; F Hiepe; F Houssiau; P Lesavre; L Lightstone; Pl Meroni; O Meyer; B Moulin; K O'Reilly; M Praga; H Schulze-Koops; Ra Sinico; Kgc Smith; A Tincani; C Vasconcelos; G Hughes
Journal:  Lupus       Date:  2009-03       Impact factor: 2.911

10.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103

View more
  4 in total

1.  Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model.

Authors:  D A C Botte; I L Noronha; D M A C Malheiros; T V Peixoto; S B V de Mello
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

Review 2.  Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis.

Authors:  Marianne Frieri; William Heuser; Joshua Bliss
Journal:  J Pharmacol Pharmacother       Date:  2015 Apr-Jun

3.  Lupus nephritis: low urinary DNase I levels reflect loss of renal DNase I and may be utilized as a biomarker of disease progression.

Authors:  Hege L Pedersen; Kjersti D Horvei; Dhivya Thiyagarajan; Gudrun E Norby; Natalya Seredkina; Gabriella Moroni; Gro Ø Eilertsen; Hallvard Holdaas; Erik H Strøm; Gunnstein Bakland; Pier-Luigi Meroni; Ole P Rekvig
Journal:  J Pathol Clin Res       Date:  2018-04-06

4.  A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis.

Authors:  Hong Wang; Yi-le Ren; Jun Chang; Luo Gu; Ling-Yun Sun
Journal:  Arch Rheumatol       Date:  2017-07-25       Impact factor: 1.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.